Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression.
Castagna A, Monno L, Carta S, Galli L, Carrara S, Fedele V, Punzi G, Fanti I, Caramello P, Lepri AC, De Luca A, Ceccherini-Silberstein F, Monforte AD; ICONA Foundation Study Group. Castagna A, et al. Among authors: monforte ad. Medicine (Baltimore). 2016 Nov;95(44):e5222. doi: 10.1097/MD.0000000000005222. Medicine (Baltimore). 2016. PMID: 27858869 Free PMC article.
Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.
Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, Melzi S, De Luca A, Monforte AD, Antinori A; Adherence Italian Cohort Naive Antiretrovirals (AdICONA) Study Group; Adherence Spallanzani (AdeSpall) Study Group. Trotta MP, et al. Among authors: monforte ad. AIDS. 2003 May 2;17(7):1099-102. doi: 10.1097/00002030-200305020-00026. AIDS. 2003. PMID: 12700467
Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study.
Murri R, Lepri AC, Phillips AN, Girardi E, Nasti G, Ferrara S, Mura MS, Mussini C, Petrelli E, Arlotti M, De Stefano C, Vigano P, Novati R, Cargnel A, Monforte AD; I.Co.N.A. Study Group. Murri R, et al. Among authors: monforte ad. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):184-90. doi: 10.1097/00126334-200310010-00008. J Acquir Immune Defic Syndr. 2003. PMID: 14526207
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
Svicher V, Ceccherini-Silberstein F, Erba F, Santoro M, Gori C, Bellocchi MC, Giannella S, Trotta MP, Monforte Ad, Antinori A, Perno CF. Svicher V, et al. Among authors: monforte ad. Antimicrob Agents Chemother. 2005 May;49(5):2015-25. doi: 10.1128/AAC.49.5.2015-2025.2005. Antimicrob Agents Chemother. 2005. PMID: 15855527 Free PMC article.
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group. Antonucci G, et al. Among authors: monforte ad. Clin Infect Dis. 2005 Jun 15;40(12):e101-9. doi: 10.1086/430445. Epub 2005 May 5. Clin Infect Dis. 2005. PMID: 15909251
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
Carosi G, Puoti M, Antonucci G, De Luca A, Maserati R, Torti C, Bonfanti P, Bonora S, Bruno R, Gaeta GB, Antinori A, Monforte Ad, Orani A, Sagnelli E, Cargnel A, Cauda R, Mazzotta F, Pastore G, Suter F, Vullo V; Italian ART; HCV-HIV Coinfection Working Group. Carosi G, et al. Among authors: monforte ad. AIDS Rev. 2005 Jul-Sep;7(3):161-7. AIDS Rev. 2005. PMID: 16302464
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study.
Murri R, Lepri AC, Cicconi P, Poggio A, Arlotti M, Tositti G, Santoro D, Soranzo ML, Rizzardini G, Colangeli V, Montroni M, Monforte AD; ICoNA Study Group. Murri R, et al. Among authors: monforte ad. J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):23-30. doi: 10.1097/01.qai.0000188337.76164.7a. J Acquir Immune Defic Syndr. 2006. PMID: 16340469
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
Cozzi-Lepri A, De Luca A, Phillips AN, Bongiovanni M, Di Giambenedetto S, Mena M, Moioli MC, Arlotti M, Sighinolfi L, Narciso P, Lichtner M, Cauda R, Monforte Ad; ICoNA Study Group; UCSC-Roma HIV Cohort Study Group; IMIT Study Group. Cozzi-Lepri A, et al. Among authors: monforte ad. J Infect Dis. 2006 Jul 1;194(1):20-8. doi: 10.1086/504265. Epub 2006 May 16. J Infect Dis. 2006. PMID: 16741878 Free article.
261 results